Propanc Biopharma Inc (NASDAQ:PPCB – Get Free Report) was the recipient of a large drop in short interest in the month of October. As of October 30th, there was short interest totaling 19,745 shares, a drop of 60.9% from the October 15th total of 50,470 shares. Based on an average daily volume of 57,444 shares, the short-interest ratio is presently 0.3 days. Approximately 4.7% of the shares of the stock are short sold.
Propanc Biopharma Price Performance
NASDAQ PPCB traded down $0.05 during trading on Monday, reaching $1.89. The company’s stock had a trading volume of 8,490 shares, compared to its average volume of 170,750. The stock has a market capitalization of $1.19 million, a PE ratio of -0.01 and a beta of 3.55. The firm has a fifty day moving average of $4.57 and a 200 day moving average of $20.32. Propanc Biopharma has a one year low of $1.63 and a one year high of $315.00.
Propanc Biopharma (NASDAQ:PPCB – Get Free Report) last released its quarterly earnings results on Friday, November 13th. The company reported ($12.22) earnings per share for the quarter.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings cut shares of Propanc Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, August 26th. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock has an average rating of “Sell”.
Check Out Our Latest Stock Report on Propanc Biopharma
Propanc Biopharma Company Profile
Propanc Biopharma, Inc. (NASDAQ:PPCB) is a clinical-stage biotechnology company focused on developing novel treatments for solid tumors, including pancreatic, ovarian and colorectal cancers. The company’s research is based on proenzyme therapy, an approach intended to selectively target cancer cells and cancer stem cells while limiting tumor growth, recurrence and metastasis. Propanc’s lead investigational product is PRP, also referred to as PRP-100, an intravenous formulation comprising the naturally occurring digestive proenzymes trypsinogen and chymotrypsinogen.
See Also
- Five stocks we like better than Propanc Biopharma
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Propanc Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Propanc Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
